NTLA Earnings Prediction
The chart below shows how NTLA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NTLA sees a -2.42% change in stock price 10 days leading up to the earnings, and a +0.10% change 10 days following the report. On the earnings day itself, the stock moves by -0.38%. This data can give you a slight idea of what to expect for the next quarter's release.
NTLA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
12.87M
771.57%
41.30%
Gross Margin
--
--
--
Operating Margin
-1059.86%
-25.39%
-33.30%
Net Margin
-1001.23%
-24.52%
-32.78%
EPS
-1.27
-13.01%
-5.22%
No Data Available
NTLA Earnings Analysis
Intellia Therapeutics Inc Corporation (NTLA.O) Earnings Conference Call
Positive
Operational Execution and Enrollment: Strong start in 2025 with operational execution and increased enrollment in late-stage studies.
Phase III Enrollment Progress: Positive enrollment progress in Phase III studies for NTLA-2002 and transthyretin amyloidosis, with expectations to complete enrollment in 2025.
Phase I Trial Results: Encouraging data from Phase I trial of nex-z showing significant TTR reduction, potentially impacting disease progression in ATTR amyloidosis patients.
Phase III Study Initiation: First patient dosed in Phase III study for NTLA-2002, with high interest from patients and investigators, indicating rapid enrollment and potential for commercial uptake.
High-Value Program Launches: Pipeline prioritization focusing on high-value programs, with plans for three launches between 2027 and 2030.
Leadership in Drug Development: Newly appointed Chief Scientific Officer, Birgit Schultes, brings extensive experience in drug development and gene editing technologies.
Strong Financial Reserves: Solid financial position with approximately $861.7 million in cash and marketable securities, allowing for continued pipeline execution.
Collaboration Revenue Surge: Collaboration revenue increased significantly due to Regeneron agreement, indicating strong partnerships and financial growth.
Restructuring for Financial Health: Expected decline in GAAP operating expenses due to restructuring, allowing for investments in commercial infrastructure while maintaining financial health.
Negative
Cash Reserves Decline: Intellia's cash reserves decreased from $1 billion at the end of 2023 to approximately $861.7 million by the end of 2024, indicating a significant reduction in financial resources.
R&D Expense Increase: R&D expenses increased to $116.9 million in Q4 2024 from $109 million in Q4 2023, suggesting rising costs associated with advancing their lead programs.
Rising G&A Expenses: G&A expenses also rose to $32.4 million in Q4 2024 from $29 million in the same quarter last year, primarily due to stock-based compensation, indicating increasing operational costs.
Restructuring and Workforce Reductions: The company announced a restructuring on January 9, which included workforce reductions and the discontinuation of certain programs like NTLA-3001, reflecting challenges in maintaining operational efficiency.
Wind Down Costs Impact: Intellia expects to incur wind down costs associated with discontinued programs, which may impact their financial stability in the short term.
Sales and Marketing Investments: Despite a positive outlook for future revenue from commercial launches, the company anticipates significant sales and marketing investments in 2027, which could strain financial resources during that period.
NTLA FAQs
How does NTLA typically perform around its earnings report dates?
Is Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NTLA Earning Call Sentiment
Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript
NTLA.O
3.44%Positive
The earnings call highlights strong financial performance with a significant increase in collaboration revenue and a strategic focus on R&D. The company is undergoing restructuring to reduce operating expenses, which is expected to benefit financials in 2025. The Q&A section reveals positive enrollment rates in trials and confidence in competitive positioning. Despite some uncertainties in management responses, the overall sentiment is positive, especially with the potential success of NTLA-2002 and a strong cash position. Given the market cap, a 2% to 8% stock price increase is likely.
